Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

From consumer to healthcare, here's a list of key deals reported this week: Papa John's (NASDAQ:PZZA) jumped 18% on a report that a Qatari-backed investor is considering a takeover of the pizza chain.

On the political front, Robert F. Kennedy Jr. will become the next HHS secretary after he attained a majority of Senate votes ...

Blackstone (NYSE:BX) and Corsair Capital are looking to sell First Eagle Investment Management for more than $4B, the Financial Times reported late Friday, citing people briefed on the matter.

Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug Adcetris and a tablet formulation of Roche’s R ...

We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...

RxTechExam and the Pennsylvania Pharmacists Association announced a strategic partnership. Roche’s $8 billion InterMune acquisition has been handed to a specialty pharmaceutical company, Cayman ...

Ianalumab, for the treatment of primary immune thrombocytopenia, was granted FDA orphan designation, according to a post on the ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

Acquisition includes abelacimab, a Factor XI-inhibiting monoclonal antibody in development for stroke prevention in patients ...

UBS analyst Matthew Weston downgraded Novartis (NVS) to Neutral from Buy with a price target of CHF 104, down from CHF 111. The firm believes ...

In this week's InnovationRx newsletter, federal judges halt Trump's cuts to NIH research payments, rural hospitals' ongoing ...